MC1R

MC1R is a cell-surface G protein-coupled receptor that controls the eumelanin/pheomelanin switch in melanocytes by transducing melanocortin signals into a cAMP-PKA cascade that activates melanogenic gene expression [PMID:bio_10.1101_2024.11.21.624608]. Ligand engagement is central to its output: a derived substitution that reduces MC1R affinity for both the agonist α-MSH and the antagonist ASIP shifts coat color toward brown, establishing that MC1R ligand-binding affinity sets the pigment-type decision [PMID:bio_10.1101_2025.11.14.688436], and MC1R binds melanocortin agonists (α-MSH, MTII) with high affinity while binding the inverse agonist AgRP weakly [PMID:bio_10.1101_2025.08.08.669345]. Downstream of receptor activation, signaling proceeds through cAMP and PKA, and ectopic ARHGAP36 suppresses melanogenesis by lowering PKA catalytic subunit levels without impairing MC1R itself or its cAMP stimulation, placing this brake below the receptor [PMID:bio_10.1101_2024.11.21.624608]. MC1R surface abundance is set by ubiquitin-dependent turnover: the E3 ligase MGRN1, acting through the transmembrane adapters ATRN and ATRNL1, ubiquitinates and degrades MC1R, so that MGRN1 loss raises MC1R surface levels and enhances eumelanin production [PMID:bio_10.1101_2025.03.25.645338]. Consistent with its instructive role, severe truncation of MC1R is associated with a pheomelanin-predominant coat [PMID:bio_10.1101_2025.01.22.633987], and elevating MC1R-cAMP signaling can drive melanin synthesis even in mis-trafficked endolysosomal compartments when luminal pH is near-neutral [PMID:bio_10.1101_2024.07.08.602505].

1. 2024 Medium

   Established that MC1R signals through cAMP-PKA to activate melanogenic genes and localized a melanogenesis brake (ARHGAP36) downstream of the receptor rather than at MC1R itself.

   Evidence Single-cell RNA-seq of fetal cat skin, genetic mapping of a Sex-linked orange deletion, and biochemical measurement of PKA catalytic subunit levels in melanocytes

   PMID:bio_10.1101_2024.11.21.624608

   Open questions at the time

   • Does not resolve how ARHGAP36 lowers PKA catalytic subunit levels mechanistically
   • Preprint from a single lab
   • Direct effect on endogenous human MC1R signaling not tested
2. 2024 Medium

   Showed that MC1R-cAMP signaling can drive melanin production even when melanin synthesis is displaced to non-melanosomal compartments, decoupling the signaling output from melanosome identity.

   Evidence Pharmacological cAMP elevation, genetic and lysosomotropic pH manipulation, and subcellular fractionation/imaging in BLOC-1-deficient melanocytes

   PMID:bio_10.1101_2024.07.08.602505

   Open questions at the time

   • Whether endogenous MC1R ligand engagement (vs pharmacological cAMP) produces the same effect not established
   • Luminal pH requirement quantified only indirectly
   • Single preprint
3. 2025 Medium

   Demonstrated that MC1R ligand-binding affinity itself sets the eumelanin/pheomelanin switch, by linking a single affinity-reducing substitution to a coat-color change.

   Evidence In vitro cellular binding/affinity assays comparing wild-type and variant MC1R against ASIP and α-MSH

   PMID:bio_10.1101_2025.11.14.688436

   Open questions at the time

   • Downstream cAMP/PKA consequences of the affinity change not directly measured
   • Single method, single preprint
   • Effect on agonist vs antagonist balance in vivo not dissected
4. 2025 Medium

   Defined the post-translational control of MC1R surface levels, identifying MGRN1 as the E3 ligase that degrades MC1R via ATRN/ATRNL1 adapters and linking receptor abundance to eumelanin output.

   Evidence Reciprocal Co-IP of MGRN1 with ATRN/ATRNL1 and MC1R, ubiquitination/degradation assays, and surface-level and eumelanin measurements in MGRN1-deficient melanocytes

   PMID:bio_10.1101_2025.03.25.645338

   Open questions at the time

   • Ubiquitination sites on MC1R not mapped
   • Whether ATRN and ATRNL1 act redundantly or distinctly unresolved
   • Single preprint
5. 2025 Medium

   Characterized MC1R's pharmacological profile (high α-MSH/MTII affinity, low AgRP affinity) and exploited its scaffold to build an α-MSH biosensor, distinguishing G protein from β-arrestin and internalization behaviors.

   Evidence Receptor engineering with circularly permuted GFP, G protein activation, β-arrestin coupling and internalization assays, and in vivo hypothalamic imaging

   PMID:bio_10.1101_2025.08.08.669345

   Open questions at the time

   • Engineered sensor shows impaired G protein activation, so its trafficking behavior may not reflect native MC1R
   • β-arrestin and internalization properties of wild-type MC1R not separately quantified
   • Single preprint
6. 2025 Low

   Provided in vivo correlative support that MC1R loss-of-function biases pigmentation toward pheomelanin, via a truncating mutation associated with a pheomelanin-dominant coat.

   Evidence Genomic sequencing of MC1R in marsupials with genetic association of a nonsense mutation to the xanthic coat phenotype

   PMID:bio_10.1101_2025.01.22.633987

   Open questions at the time

   • Candidate association without functional in vitro or in vivo rescue
   • Other pigmentation loci not excluded
   • Single preprint

• How ligand affinity, receptor surface abundance (MGRN1/ATRN), and downstream PKA modulation (ARHGAP36) are integrated quantitatively to set the eumelanin/pheomelanin ratio in a given melanocyte remains unresolved.
• No structural model of MC1R bound to agonist vs antagonist in the corpus
• Ubiquitination sites and degradation kinetics unmapped
• Relative contribution of each regulatory layer to pigment-type switching unquantified